| Literature DB >> 35323512 |
Shun-Zhi Liu1, Guang-Xin Xu2, Feng-Ming He1, Wei-Bo Zhang3, Zhen Wu1, Ming-Yu Li1, Xi-Xiang Tang2, Ying-Kun Qiu1.
Abstract
Four new dimeric sorbicillinoids (1-3 and 5) and a new monomeric sorbicillinoid (4) as well as six known analogs (6-11) were purified from the fungal strain Hypocrea jecorina H8, which was obtained from mangrove sediment, and showed potent inhibitory activity against the tea pathogenic fungus Pestalotiopsis theae (P. theae). The planar structures of 1-5 were assigned by analyses of their UV, IR, HR-ESI-MS, and NMR spectroscopic data. All the compounds were evaluated for growth inhibition of tea pathogenic fungus P. theae. Compounds 5, 6, 8, 9, and 10 exhibited more potent inhibitory activities compared with the positive control hexaconazole with an ED50 of 24.25 ± 1.57 µg/mL. The ED50 values of compounds 5, 6, 8, 9, and 10 were 9.13 ± 1.25, 2.04 ± 1.24, 18.22 ± 1.29, 1.83 ± 1.37, and 4.68 ± 1.44 µg/mL, respectively. Additionally, the effects of these compounds on zebrafish embryo development were also evaluated. Except for compounds 5 and 8, which imparted toxic effects on zebrafish even at 0.625 μM, the other isolated compounds did not exhibit significant toxicity to zebrafish eggs, embryos, or larvae. Taken together, sorbicillinoid derivatives (6, 9, and 10) from H. jecorina H8 displayed low toxicity and high anti-tea pathogenic fungus potential.Entities:
Keywords: Hypocrea jecorina H8; tea pathogenic fungus inhibitory effect; toxicity assessment; trichodermolide C, D
Mesh:
Substances:
Year: 2022 PMID: 35323512 PMCID: PMC8955853 DOI: 10.3390/md20030213
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1–11 isolated from an extract of Hypocrea jecorina H8; the relative configuration of 5 is reported in this article.
1H NMR (600 Hz) and 13C NMR (150 Hz) data of 1–2 (CDCl3) and 4 (DMSO-d6).
| NO. | 1 | Trichodermolide B | 2 | 4 | |||
|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||
| 2 | 174.9 | 174.7 | 176.4 | 113.6 | |||
| 3 | 55.7 | 55.9 | 56.2 | 159.9 | |||
| 4 | 149.2 | 150.9 | 152.1 | 111.7 | |||
| 5 | 134.4 | 133.9 | 133.8 | 160.3 | |||
| 6 | 191.3 | 191.2 | 191.9 | 7.34 | 118.4 | ||
| 7 | 86.8 | 86.5 | 87.1 | 125.1 | |||
| 8 | 1.77 s | 11.6 | 11.9 | 1.87 s | 12.1 | 2.89 dd (16.9, 13.7) | 192.1 |
| 9 | 1.48 s | 16.4 | 16.5 | 1.56 s | 17.3 | 4.64 dt (13.7, 2.6) | 39.8 |
| 10 | 1.30 dq (13.7, 7.2) | 20.5 | 20.5 | 2.21 dq (14.2, 7.3) | 20.9 | 3.09 td (8.5, 1.5) | 77.1 |
| 11 | 0.95 t (7.2) | 8.4 | 8.6 | 0.97 t (7.2) | 8.6 | 3.88 dq (13.6, 6.0) | 76.8 |
| 12 | 3.55 d (18.2) | 44.5 | 44.7 | 2.60 dd (13.7, 9.6) | 39.2 | 1.19 d (6.0) | 65.9 |
| 13 | 204 | 205.0 | 4.10 m | 67.1 | 2.04 s | 21.5 | |
| 14 | 2.27 s | 30.3 | 30.5 | 1.29 t (7.2) | 24.1 | 2.12 s | 9.2 |
| 15 | 3.55 t (5.3) | 49.9 | 50.0 | 2.97 dd (6.4, 4.4) | 51.3 | 16.7 | |
| 16 | 2.43 dd (18.5, 5.2) | 35.2 | 35.0 | 1.52 m | 32.3 | ||
| 17 | 196.5 | 197.2 | 4.17 m | 71.1 | |||
| 18 | 6.43 br dd (15.4, 10.2) | 127.9 | 127.6 | 6.16 dd (15.2, 10.5) | 132.1 | ||
| 19 | 7.25 dd (15.2, 10.8) | 143.0 | 143.9 | 5.44 dd (15.2, 7.2) | 131.9 | ||
| 20 | 6.20 d (15.4) | 128.8 | 130.6 | 5.75 dq (14.3, 6.8) | 131.7 | ||
| 21 | 6.35 dt (15.2, 4.8) | 143.2 | 141.9 | 5.99 dd (15.2, 10.7) | 130.0 | ||
| 22 | 4.32 d (4.2) | 62.7 | 19.1 | 1.76 br d (6.6) | 18.2 | ||
Figure 2Key 1H–1H COSY, HMBC, and NOESY correlations of compounds 1–5. (a) Key COSY, HMBC, and NOESY correlations of compounds 1; (b) Key COSY, HMBC, and NOESY correlations of compounds 2; (c) Key COSY, HMBC, and NOESY correlations of compounds 3; (d) Key COSY, HMBC correlations of compounds 4; (e) Key COSY, HMBC, and NOESY correlations of compounds 5.
Figure 3Calculated and experimental ECD spectra of compounds 1, 2, and 3. (a) ECD spectra for compound 1; (b) ECD spectra for compound 2; (c): ECD spectra for compound 3.
1H NMR (600 Hz) and 13C NMR (150 Hz) data of 3, 5 (CDCl3) and 13C NMR data of Compounds 10 and 11.
| NO. | 3 | 10 | NO. | 5 | 11 | ||
|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||
| 1 | 2.94, s | 58.3 | 57.5 | 1 | 191.8 | 194.3 | |
| 1′ | 3.31, s | 52.3 | 57.5 | 2 | 100.7 | 101.9 | |
| 2,2′ | 78.3 | 78.9 | 3 | 2.58 br d (14.1) | 35.9 | 35.4 | |
| 3,3′ | 108.7 | 104.1 | 4 | 73.9 | 72.7 | ||
| 4 | 59.0 | 58.8 | 5 | 168.7 | 168.8 | ||
| 4′ | 59.0 | 58.8 | 6 | 103.9 | 105.6 | ||
| 5,5′ | 199.0 | 198.0 | 7 | 191.7 | 191.6 | ||
| 6′ | 104.0 | 102.8 | 8 | 106.1 | 106.2 | ||
| 6 | 103.8 | 102.8 | 1′ | 179.7 | 178.0 | ||
| 7 | 172.5 | 175.9 | 2′ | 6.40 br d (14.9) | 120.3 | 121.4 | |
| 7′ | 175.2 | 175.9 | 3′ | 7.25 br s | 139.0 | 137.8 | |
| 8 | 6.18 d (14.7) | 118.6 | 118.5 | 4′ | 6.21 m | 130.8 | 131.4 |
| 8′ | 2.38 dd (16.9, 3.5) | 40.9 | 118.5 | 5′ | 6.10 br d (7.0) | 131.1 | 131.7 |
| 9 | 7.35 dd (14.8,10.9) | 143.0 | 143.6 | 6′ | 1.86 br d (6.4) | 18.8 | 18.9 |
| 9′ | 4.31 ddd (13.5, 7.1,3.2) | 80.7 | 143.6 | 1″ | 168.8 | 167.3 | |
| 10 | 6.31 dd (15.4, 11.0) | 130.8 | 130.9 | 2″ | 6.27 m | 120.2 | 121.3 |
| 10′ | 5.67 dq (15.2,6.6) | 131.8 | 130.9 | 3″ | 6.29 m | 140.3 | 140.1 |
| 11 | 6.22 dd (13.6,6.6) | 140.1 | 140.5 | 4″ | 6.23 br s | 131.8 | 131.4 |
| 11′ | 5.49 ddd (15.3,7.0,1.6) | 127.2 | 140.5 | 5″ | 6.18 m | 137.0 | 136.6 |
| 12 | 1.91 brd (6.6) | 18.9 | 18.8 | 6″ | 1.86 br d (6.4) | 18.9 | 19.1 |
| 12′ | 1.68 brd (6.4) | 17.8 | 18.8 | 1a | 58.4 | 59.1 | |
| 13 | 1.43 s | 21.5 | 21.3 | 1a-CH3 | 1.34 s | 19.2 | 19.9 |
| 13′ | 1.35 s | 20.7 | 21.3 | 4a | 110.2 | 108.4 | |
| 14 | 1.41 s | 18.2 | 18.9 | 4-CH3 | 1.29, s | 22.4 | 22.8 |
| 14′ | 1.41 s | 18.4 | 18.9 | 5a | 79.6 | 78.8 | |
| 5a-CH3 | 1.48 br s | 25.6 | 25.8 | ||||
| 6-CH3 | 1.53, s 1.86 br d (6.4) | 6.8 | 7.3 | ||||
| 8a | 3.63, s | 53.6 | 53.6 | ||||
Antifungal activities of 5, 6, 8, 9, and 10 (ED50, µg/mL).
| Compd. |
| Compd. |
|
|---|---|---|---|
| 1 | >100 | 8 | 18.22 ± 1.29 |
| 2 | >100 | 9 | 1.83 ± 1.37 |
| 3 | >100 | 10 | 4.68 ± 1.44 |
| 4 | >100 | 11 | >100 |
| 5 | 9.13 ± 1.25 | hexaconazole * | 24.25 ± 1.57 |
| 6 | 2.04 ± 1.91 | DMSO | None |
| 7 | >100 |
* hexaconazole serves as positive control.
Figure 4Embryotoxicity and developmental toxicity assay; 15 zebrafish embryos per condition were exposed to compounds at the concentrations of 10, 5, 2.5, 1.25, and 0.625 μM, and 0.1% DMSO was used as blank control. (a) The mortality rate of 24 embryo treated with compounds; (b) The mortality rate of 72 embryo treated with compounds; (c) The impact on the malformation of zebrafish treated with compounds) The statistics of 24 and 72 h mortality rate; © Morphology of 24 h embryo or 72 h zebrafish larvae treated with compounds or control.